Canada: Supreme Court Of Canada: VIAGRA Patent "Void" For Insufficient Disclosure

The Supreme Court of Canada today released the hotly anticipated decision in Teva Canada Limited v Pfizer Canada Inc, 2012 SCC 60 (sildenafil, VIAGRA). In a unanimous decision written by Justice LeBel, the Court found that the patent failed to satisfy the disclosure requirements of the Patent Act.

Background

The '446 Patent. The patent at issue, Canadian Patent No. 2,163,446 ("'446"), discloses and claims a new use for a class of compounds, namely the treatment of erectile dysfunction ("ED"). In particular, the patent describes:

  • four broad groups of compounds (a general class, "preferred," "more preferred" and "particularly preferred" compounds); and
  • an especially preferred group of nine specifically identified compounds, one of which is sildenafil (the active ingredient in VIAGRA).

While the patent asserts that one especially preferred compound "induces penile erection in impotent males," the patent provides only a summary description of the study and does not identify the specific compound tested or present the data obtained.

The patent claims the new use for various classes of compounds and for the nine especially preferred compounds (as a group). The patent also claims the new use for two compounds individually, including sildenafil (claim 7).

Key statutory provision. Section 27 of the Patent Act is the statutory provision governing disclosure of inventions. The key provision before the Court was section 27(3)(a), which provides:

(3) The specification of an invention must

(a) correctly and fully describe the invention and its operation or use as contemplated by the inventor;

Judicial History

Teva (then Novopharm) alleged that the '446 patent was invalid, including for inutility and insufficiency of disclosure. In response, Pfizer commenced an application under the Patented Medicines (Notice of Compliance) Regulations ("PMNOC Regulations"). Pfizer succeeded at first instance and on appeal.

Federal Court: 2009 FC 638. Teva's application was dismissed by Justice Kelen, who addressed the inutility and insufficiency issues as follows:

Inutility. Pfizer introduced evidence of a patient study for sildenafil ("Study 350"). Justice Kelen ruled that Study 350 demonstrated utility and that evidence of demonstrated utility was not required to be included in the patent disclosure.

Insufficiency of disclosure. Justice Kelen ruled that the question must be considered for the specific claim in issue. Hence, the Court needed to consider whether the invention of claim 7 was sufficiently disclosed. Justice Kelen found that (i) sildenafil was the only compound in the patent found to induce erections, and (ii) the skilled person would not have known from the specification that the tested compound was sildenafil. However, he found that the skilled person could conduct tests on the two individual compounds claimed and determine which compound worked.

While Justice Kelen rejected the insufficiency allegation, he did so only grudgingly, expressing significant concerns in obiter about the patentee's failure to identify the tested compound:

[136] By withholding from the public the identity of the only compound tested and found to work, sildenafil, the patent did not fully describe the invention. Obviously Pfizer made a conscious choice not to disclose the identity of the only compound found to work, and left the skilled reader guessing. This is contrary to the statutory requirement to fully disclose the invention. [emphasis added]

Federal Court of Appeal: 2010 FCA 242. On appeal, the Federal Court of Appeal upheld the decision of Justice Kelen. The Court agreed that the sufficiency of disclosure should be assessed through the prism of claim 7. The patent was sufficient since it answered the questions posed by the Supreme Court in Consolboard Inc v MacMillan Bloedel, [1981] 1 S.C.R. 504 ("Consolboard"): "What is your invention?" and "How does it work?" The Court also upheld Justice Kelen on the question of utility.

Supreme Court of Canada: 2012 SCC 60. The focus of the decision is whether Pfizer properly disclosed the invention of the '446 patent. The Court also commented on utility.

Insufficiency of disclosure. The Court stated that "the first step is to define the nature of the invention" in the '446 patent. The Courts below had treated each claim as a separate invention and therefore considered the disclosure requirements with respect to each individual claim, not to the specification as a whole. The Court rejected the claim-based approach, preferring to consider the specification as a whole. The Court left open the possibility that different claims may disclose separate inventions, but this must be determined on a case-by-case basis.

Turning to the '446 patent, the Court found only one inventive concept: the use of sildenafil and other compounds in the treatment of ED (i.e. it did not accept that the use of sildenafil was a distinct invention). The Court relied on the following factors:

  • "No specific attributes or characteristics are ascribed to sildenafil that would set it apart from the other compounds."
  • "...nothing ...distinguishes it [sildenafil] from the other eight 'especially preferred compounds.'"
  • "...the patent itself suggests that the entire class of claimed compounds will be effective in treating ED." "The plural word 'inventions' does not appear in Patent '446."
  • "There is no evidence on the record to suggest that Pfizer filed a divisional application...".

As to whether the disclosure was sufficient, the Court began with Pfizer's actual work (presumably to determine what Pfizer actually invented) before turning to the specification to see whether Pfizer had disclosed that invention.

As Pfizer only conducted tests that demonstrated that sildenafil was effective and none of the other compounds had been shown to be effective, the Court concluded that the invention was the use of sildenafil for the treatment of ED. As the Court noted: "This had to be disclosed in order to meet the requirements set out in s. 27(3) of the Act."

In considering the invention disclosed by the specification, the Court noted that "the specification does not indicate that sildenafil is the effective compound." Further, the disclosure would not enable the public to make the same successful use of the invention as the inventor since, even if a skilled reader could have narrowed the effective compound down to the two compounds that were individually claimed, further testing was necessary to determine which of the compounds actually worked.

In rejecting Pfizer's argument that Teva had been able to make use of the invention having only the specification because it had filed a submission for regulatory approval, the Court stated:

However, this does not change the fact that the specification required, at a minimum, "a minor research project" in order to determine whether Claim 6 or Claim 7 contained the correct compound. The fact that Teva carried out this minor research project is irrelevant to Pfizer's obligation to fully disclose the invention. More importantly, what must be considered is whether a skilled reader having only the specification would have been able to put the invention into practice. The trial judge clearly found that the skilled reader would have had to undertake a minor research project to determine what the true invention was.

The Court found that the courts below misread Consolboard when they stated that the only questions that must be answered are "What is your invention?" and "How does it work?". The Court indicated that these were not the only relevant questions, noting that the description must enable a skilled person to produce the invention using only the instructions contained in the disclosure: "Whether or not a specification is sufficient depends on what a skilled person would consider to be sufficient...".

In concluding that the '446 patent was insufficient, the Court commented on the practice of cascading claims (broad genus claims that progressively narrow). According to the Court, such claims do not necessarily interfere with the public's right to disclosure since the useful claim is usually the claim at the end for the individual compound. The problem in this case was that the "claims ended with two individually claimed compounds, thereby obscuring the true invention."

The Court provides a stark warning to patentees on the need to make full disclosure:

...Pfizer gained a benefit from the Act — exclusive monopoly rights — while withholding disclosure in spite of its disclosure obligations under the Act. As a matter of policy and sound statutory interpretation, patentees cannot be allowed to "game" the system in this way. This, in my view, is the key issue in this appeal. It must be resolved against Pfizer.

As a result of the failure to properly disclose the invention, the Court ruled that the '446 patent is invalid and void. This appears to have been an oversight by the Court given that the proceeding arose under the PMNOC Regulations and the only issue was whether the allegation of invalidity was justified. Accordingly, the Court would not appear to have jurisdiction on this appeal to void the patent.

Utility. Teva had argued that claim 7 is invalid for insufficient disclosure of sound prediction. The Court rejected this argument. As the patent stated that the claimed compound will be useful in treating ED and at the time the application was filed sildenafil could assist in treating ED, the Court found that this "is all that is required." The failure to identify the tested compound went to the issue of disclosure of the invention, not to disclosure of the invention's utility. The Court expressly rejected the notion of a separate disclosure requirement for utility under section 27(3).

On the issue of whether an "enhanced" disclosure requirement exists for sound prediction, as has been suggested in decisions of the Federal Court of Appeal, the Court found that sound prediction was not in issue and declined to comment on the question.

Conclusion

While the Court took some care to limit the decision to the peculiar facts of the case, this decision will almost certainly give rise to vigorous challenges by generic drug manufacturers on the basis of insufficiency of disclosure. Perhaps the most troubling aspect of the decision is the Court's emphasis on looking to the disclosure, rather than the issued claims, to divine the nature of the invention.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Colin B. Ingram
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions